TY - JOUR
T1 - Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure
T2 - Consequences on susceptibility to cell-mediated cytotoxicity
AU - Terry, Stéphane
AU - Buart, Stéphanie
AU - Tan, Tuan Zea
AU - Gros, Gwendoline
AU - Noman, Muhammad Zaeem
AU - Lorens, James B.
AU - Mami-Chouaib, Fathia
AU - Thiery, Jean Paul
AU - Chouaib, Salem
N1 - Funding Information:
We thank Sophie Salom? (Imaging and Cytometry Platform, Institut Gustave Roussy) for advice with confocal microscopy. We thank Aur?lie Durgeau, Linda Ziani, Meriem Hasmim, Marine Leclerc and Mehdi Khaled for discussion and technical advice. This work was supported in part by the Institute of Molecular Cell Biology (core funding A*STAR, Singapore, JPT), the Ligue contre le Cancer (?quipe labellis?e, SC) and by grants from Institut National du Cancer and Gustave Roussy (INCa PLBIO15-266, SIRIC-SOCRATE).
Publisher Copyright:
© 2017 Taylor & Francis Group, LLC.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Tumor escape to immunosurveillance and resistance to immune attacks present a major hurdle in cancer therapy, especially in the current era of new cancer immunotherapies. We report here that hypoxia, a hallmark of most solid tumors, orchestrates carcinoma cell heterogeneity through the induction of phenotypic diversity and the acquisition of distinct epithelial–mesenchymal transition (EMT) states. Using lung adenocarcinoma cells derived from a non-metastatic patient, we demonstrated that hypoxic stress induced phenotypic diversity along the EMT spectrum, with induction of EMT transcription factors (EMT-TFs) SNAI1, SNAI2, TWIST1, and ZEB2 in a hypoxia-inducible factor-1α (HIF1A)-dependent or -independent manner. Analysis of hypoxia-exposed tumor subclones, with pronounced epithelial or mesenchymal phenotypes, revealed that mesenchymal subclones exhibited an increased propensity to resist cytotoxic T lymphocytes (CTL), and natural killer (NK) cell-mediated lysis by a mechanism involving defective immune synapse signaling. Additionally, targeting EMT-TFs, or inhibition of TGF-β signaling, attenuated mesenchymal subclone susceptibility to immune attack. Together, these findings uncover hypoxia-induced EMT and heterogeneity as a novel driving escape mechanism to lymphocyte-mediated cytotoxicity, with the potential to provide new therapeutic opportunities for cancer patients.
AB - Tumor escape to immunosurveillance and resistance to immune attacks present a major hurdle in cancer therapy, especially in the current era of new cancer immunotherapies. We report here that hypoxia, a hallmark of most solid tumors, orchestrates carcinoma cell heterogeneity through the induction of phenotypic diversity and the acquisition of distinct epithelial–mesenchymal transition (EMT) states. Using lung adenocarcinoma cells derived from a non-metastatic patient, we demonstrated that hypoxic stress induced phenotypic diversity along the EMT spectrum, with induction of EMT transcription factors (EMT-TFs) SNAI1, SNAI2, TWIST1, and ZEB2 in a hypoxia-inducible factor-1α (HIF1A)-dependent or -independent manner. Analysis of hypoxia-exposed tumor subclones, with pronounced epithelial or mesenchymal phenotypes, revealed that mesenchymal subclones exhibited an increased propensity to resist cytotoxic T lymphocytes (CTL), and natural killer (NK) cell-mediated lysis by a mechanism involving defective immune synapse signaling. Additionally, targeting EMT-TFs, or inhibition of TGF-β signaling, attenuated mesenchymal subclone susceptibility to immune attack. Together, these findings uncover hypoxia-induced EMT and heterogeneity as a novel driving escape mechanism to lymphocyte-mediated cytotoxicity, with the potential to provide new therapeutic opportunities for cancer patients.
KW - Antitumor cytotoxic response
KW - CTL
KW - EMT
KW - HIF
KW - NK cells
KW - NSCLC
KW - TGF-β
KW - hypoxia
UR - http://www.scopus.com/inward/record.url?scp=85011866928&partnerID=8YFLogxK
U2 - 10.1080/2162402X.2016.1271858
DO - 10.1080/2162402X.2016.1271858
M3 - Article
C2 - 28344883
AN - SCOPUS:85011866928
SN - 2162-4011
VL - 6
JO - OncoImmunology
JF - OncoImmunology
IS - 2
M1 - e1271858
ER -